The Desire Signal
PT-141
A melanocortin peptide studied for how the brain, not just the bloodstream, regulates desire and arousal.
7 amino acids (cyclic)
Melanocortin receptor agonist
Also known as bremelanotide
A melanocortin peptide studied for how the brain, not just the bloodstream, regulates desire and arousal.
Desire starts in the brain. Before anything happens in the body, signals in the brain's emotion and reward networks help set the stage for interest and arousal.
PT-141, whose generic name is bremelanotide, is a synthetic peptide related to alpha-MSH, a natural hormone that works through a family of receptors called melanocortin receptors. It is a seven-amino-acid peptide in a ring-shaped (cyclic) form.
Scientists noticed that an earlier melanocortin peptide, Melanotan II, had effects on sexual arousal, and that observation led to the development of PT-141.
Think of PT-141 as a message sent to the brain's desire network: researchers are studying how melanocortin signaling may influence interest and arousal.
Melanocortin receptors are found in areas of the brain, such as the hypothalamus, that help regulate appetite, energy, and sexual response.
PT-141 is believed to act on these receptors. Its exact mechanism for improving desire is not fully understood.
Many well-known sexual-function medicines work on blood flow. PT-141 is studied differently: researchers believe its effects begin with signals in the brain.
Clinical research has looked at premenopausal women with low sexual desire and, earlier, at men with erectile difficulties. Only the work in women led to an approved medicine.
The strongest evidence comes from two 24-week, placebo-controlled trials involving about 1,200 premenopausal women with low sexual desire.
In other words, the effect was real but modest on average.
Bremelanotide was developed from melanocortin research that began with Melanotan II in the 1980s and 1990s. In June 2019, the FDA approved it under the brand name Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
That approval applies to the pharmaceutical product and to that specific use. Research-grade PT-141 is not the approved medicine, and PT-141 is not approved for any other use, including in men.
PT-141 is one of the few peptides in this series studied mainly for what it does in the brain's signaling networks, rather than for repair, inflammation, or metabolism.
PT-141 is a melanocortin peptide with a clear scientific story, an approved medicine in one narrow area, and modest clinical benefits balanced by real side effects.
The Peptide Curious takeaway: Think of PT-141 as a signal to the brain's desire network. Researchers are exploring how melanocortin signaling may influence interest and arousal.
Peptide Curious provides educational and editorial content only. It is not medical advice and is not a substitute for a qualified healthcare professional. PT-141 is discussed here as a research/investigational compound; content may describe emerging research not approved for clinical use.